GlaxoSmithKline initiated a shield for its diabetes drug Avandia on Wednesday with a detailed 30-page response rejecting a critical report by U. S. lawmakers.

About 3 years back, Dr. Steven E. Nissen, a renowned cardiologist at the Cleveland Clinic, carried out a groundbreaking study which hinted that the Avandia, GlaxoSmithKline's best selling diabetes drug, significantly raised the risk of heart attacks. That is when sales of the drug and shares of Glaxo declined.

Concerns about a drug manufactured by GlaxoSmithKline linked with heart attacks are on a rise. This came following a Senate report, which is now, is putting pressure on the Food and Drug Administration to make changes to its drug-safety program.

As per a 334-page bipartisan report released by the Senate Finance committee on Saturday, drugmaker GlaxoSmithKline’s Avandia diabetes drug is associated with countless cases of heart attack – and the company, aware of the drug’s heart attack risks, has been keeping the information under wraps.

In London trading, shares of GlaxoSmithKline Plc. tumbled after the US health regulators issued a warning against the long-term use of the pharmaceutical company's popular and commonly used offering, the Advair asthma treatment. Also, the Food and Drug Administration called for further study of potential health risks.

As proposed by the US Food and Drug Administration (FDA), the UK-based pharmaceutical giant GlaxoSmithKline (GSK) is contemplating label changes for its asthma medications, like Advair, which contain LABAs, or long-acting beta-agonists.

Two competing vaccines are available for the Canadian women against HPV, the virus that cause cervical cancer.

Cervarix, a product of GlaxoSmithKline Inc., is expected to be available by early March while, Gardasil, a product of Merck Canada, is already available since 2006.

Despite soaring profits British pharmaceuticals giant GlaxoSmithKline is soon going to announce a cut up to 4,000 more jobs. The worst hit will be United States and Europe.

GlaxoSmithKline, the drug-making giant, is starting its research cupboards and labs to outside scientists in an unusual effort to trigger more research on ignored tropical diseases.

The researchers, says the British company, may be able to seek approval for the first vaccine against malaria, a mosquito-borne parasitic disease that kills a million people a year.

The Food and Drug Administration on Monday has issued a warning to consumers involving a counterfeit version of GlaxoSmithKline's weight-loss 60 milligram capsules drug Alli, which is sold over the internet.